ArticleJournal of human hypertension2007
Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus.
Article in Journal of human hypertension, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 66 citations in OpenAlex.
- Rethinking Mitochondria: The Extracellular Dimension.Circulation research · 2026Review
- Extracellular vesicles in atherothrombosis: From biomarkers and precision medicine to therapeutic targets.Immunological reviews · 2022Review
- Review
- Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.Frontiers in oncology · 2022Review
- Extracellular Vesicles in Essential Hypertension: Hidden Messengers.Current hypertension reports · 2020Review
- The role of calcium channel blockers in wound healing.Iranian journal of basic medical sciences · 2018Article
- Type 2 diabetes and older age contribute to elevated plasma microparticle concentrations independent of chronic stroke.Experimental physiology · 2018Article
- In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress.Journal of diabetes research · 2018Review
- The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.Cardiovascular drugs and therapy · 2017Review
- Clinical roles of calcium channel blockers in ischemic heart diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Review
- Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse.Frontiers in cardiovascular medicine · 2017Review
- Endothelial Microparticles Act as Novel Diagnostic and Therapeutic Biomarkers of Diabetes and Its Complications: A Literature Review.BioMed research international · 2016Review
- Microparticles as potential biomarkers of cardiovascular disease.Arquivos brasileiros de cardiologia · 2015Review
- Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets.PloS one · 2015Article
- Clinical significance of procoagulant microparticles.Journal of intensive care · 2015Review
- Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?Drug metabolism and disposition: the biological fate of chemicals · 2014Review
- Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.Acta pharmacologica Sinica · 2014Review
- Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.The open cardiovascular medicine journal · 2011Article
- Antihypertensive treatment, adiponectin and cardiovascular risk.Journal of human hypertension · 2007Review
- Microparticles and cardiovascular diseases.Annals of medicineReview
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.